Skip to content

Iguratimod for Knee Osteoarthritis: A Study on Efficacy and Safety

Iguratimod for Knee Osteoarthritis: A Study on Efficacy and Safety

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114750
Enrollment
Unknown
Registered
2025-12-17
Start date
2025-12-19
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Group1:Meloxicam tablets and Iguratimod
Group2:Meloxicam tablets and placebo

Sponsors

Beijing Jishuitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years, regardless of gender; 2.meets the diagnostic criteria for knee osteoarthritis as outlined in the Chinese Guidelines for Diagnosis and Treatment of Osteoarthritis (2024 Edition); 3.at screening, the average visual analog scale (VAS) score for pain in the target knee joint according to the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscale A was >=40 mm and <=80 mm; 4.the target knee joint was classified as Kellgren-Lawrence grade I-III, and the other knee joint was of a grade not exceeding that of the target knee; 5.voluntarily participated and provided written informed consent.

Exclusion criteria

Exclusion criteria: 1.Individuals with allergies to Iguratimod tablets, placebo, Meloxicam tablets, other non-steroidal anti-inflammatory drugs (NSAIDs), or aspirin; 2.individuals with active or newly developed gastrointestinal ulcers, perforation, or other hemorrhagic diseases; 3.individuals scheduled to undergo lower limb surgery during the study period; 4.individuals with severe hepatic or renal dysfunction, leukopenia, anemia, or thrombocytopenia; 5.female participants with a positive pregnancy test or who are lactating, or participants of childbearing potential who are unable to use effective contraception during the trial and for 6 months after the last dose, or who plan to become pregnant; 6.individuals with any other conditions deemed by the investigator as unsuitable for participation.

Design outcomes

Primary

MeasureTime frame
Change in the WOMAC pain subscale score (Subscale A) for the knee joint;

Secondary

MeasureTime frame
Total Score of the Knee Joint WOMAC Scale;Knee Joint WOMAC Scale A (Pain) Score;Knee Joint WOMAC Scale B (Stiffness) Score;Knee Joint WOMAC Scale C (Physical Function) Score;Percentage of participants with positive knee joint response;MRI images and ultrasound measurement results;SF-36 Scale Score;

Countries

China

Contacts

Public ContactDeng Xiaoli

Beijing Jishuitan Hospital, Capital Medical University

13683657545@163.com+86 10 50963060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026